The laboratory was founded in 2001.
Main areas of research
The study of the biology of mesenchymal and hematopoietic stem cells from various sources of postnatal origin.
Theoretical and experimental substantiation of the possibility of using cell therapy in the treatment of diseases of the cardiovascular and central nervous system. Development of protocols, organization and conduct of clinical studies with the use of stem cells and their derivatives with the aim of introducing cellular therapy into the public health practice.
The most significant research results
Technologies were developed to isolate and cultivate multipotent mesenchymal stromal cells (MSCs) from various sources of postnatal origin (bone marrow, adipose tissue).
For the first time in the world, the possibility of isolating MSCs from umbilical cord tissue is described - according to experts, the most promising source of cells for cell therapy.
The functional properties of MSCs from various sources are investigated; together with the State Research Center of the Russian Federation “Institute of Biomedical Problems of the Russian Academy of Sciences”, the features of functioning and intercellular interactions of MSCs and hematopoietic stem cells under hypoxia and microgravity conditions were studied; the sensitivity of human stem cells to changes in environmental factors was proved.
The technologies of isolation and cryogenic storage of a concentrate of stem (nucleus-containing) cells of human umbilical cord / placental blood, as well as a therapeutic cellular product based on them, were developed and registered.
Clinical studies of the safety and efficacy of intracoronary administration of autologous bone marrow stem cell concentrate in patients with acute myocardial infarction were conducted on a limited number of patients (the study was carried out jointly with the Institute of Clinical Cardiology of National Medical Research Center of Cardiology of the Ministry of Health of Russian Federation).
Protocols were developed and clinical studies were conducted on the safety and efficacy of the use of a concentrate of cells with nucleus from the umbilical cord / placental blood in the treatment of neurodegenerative diseases, traumatic and perinatal brain lesions. The developed medical technology is approved for the use by the Federal Service for the Supervision of Health of Russian Federation.
In the course of post-registration studies conducted jointly with the CryoCentre Stem Cell Bank and the Scientific Center for Obstetrics, Gynecology and Perinatology named after Acad. VI Kulakov, data on the safety and high therapeutic efficacy of the use of umbilical cord blood cells in the complex treatment of patients with cerebral palsy and the consequences of severe traumatic brain injury were obtained.
